X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20720) 20720
Newsletter (142) 142
Magazine Article (42) 42
Book Chapter (20) 20
Newspaper Article (8) 8
Publication (7) 7
Book / eBook (5) 5
Conference Proceeding (5) 5
Book Review (3) 3
Dissertation (2) 2
Web Resource (2) 2
Government Document (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16941) 16941
pyrimidines - therapeutic use (12605) 12605
male (8727) 8727
female (7360) 7360
imatinib mesylate (5984) 5984
middle aged (5542) 5542
animals (5482) 5482
piperazines - therapeutic use (5026) 5026
pyrimidines - pharmacology (5007) 5007
benzamides (4896) 4896
adult (4683) 4683
antineoplastic agents - therapeutic use (4621) 4621
oncology (4598) 4598
aged (3990) 3990
treatment outcome (3256) 3256
pharmacology & pharmacy (2961) 2961
pyrimidines - administration & dosage (2800) 2800
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (2668) 2668
pyrimidines - adverse effects (2609) 2609
mice (2552) 2552
hematology (2527) 2527
protein kinase inhibitors - therapeutic use (2524) 2524
cancer (2348) 2348
pyrimidines (1959) 1959
imatinib (1948) 1948
sulfonamides - therapeutic use (1824) 1824
therapy (1588) 1588
care and treatment (1573) 1573
research (1508) 1508
voriconazole (1471) 1471
analysis (1469) 1469
cell line, tumor (1461) 1461
rats (1461) 1461
protein-tyrosine kinases - antagonists & inhibitors (1451) 1451
chronic myelogenous leukemia (1385) 1385
dose-response relationship, drug (1341) 1341
mutation (1311) 1311
adolescent (1309) 1309
antineoplastic agents - pharmacology (1296) 1296
chronic myeloid-leukemia (1292) 1292
drug therapy (1277) 1277
aged, 80 and over (1271) 1271
triazoles - therapeutic use (1263) 1263
rosuvastatin calcium (1226) 1226
piperazines - pharmacology (1186) 1186
antifungal agents - therapeutic use (1172) 1172
protein kinase inhibitors - pharmacology (1149) 1149
expression (1123) 1123
chronic myeloid leukemia (1104) 1104
young adult (1092) 1092
dasatinib (1088) 1088
medicine & public health (1069) 1069
antineoplastic combined chemotherapy protocols - therapeutic use (1064) 1064
leukemia (1063) 1063
health aspects (1042) 1042
pyrimidines - pharmacokinetics (1042) 1042
chemotherapy (1037) 1037
fluorobenzenes - therapeutic use (1012) 1012
biochemistry & molecular biology (997) 997
time factors (997) 997
apoptosis (990) 990
leukemia, myelogenous, chronic, bcr-abl positive - genetics (983) 983
drug resistance, neoplasm (970) 970
pyrroles - therapeutic use (966) 966
prognosis (959) 959
pyrimidines - chemistry (940) 940
clinical trials as topic (929) 929
abridged index medicus (918) 918
tumors (913) 913
gastrointestinal stromal tumors - drug therapy (902) 902
kinases (895) 895
cell biology (879) 879
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (857) 857
antineoplastic agents - adverse effects (853) 853
piperazines - adverse effects (850) 850
benzamides - therapeutic use (849) 849
efficacy (843) 843
piperazines - administration & dosage (839) 839
proteins (832) 832
pyrazoles - therapeutic use (831) 831
medicine, general & internal (822) 822
in-vitro (799) 799
risk factors (788) 788
cell proliferation - drug effects (785) 785
apoptosis - drug effects (784) 784
antineoplastic agents (781) 781
activation (779) 779
retrospective studies (773) 773
disease models, animal (765) 765
resistance (765) 765
bcr-abl (755) 755
hematology, oncology and palliative medicine (750) 750
safety (750) 750
tyrosine kinase inhibitor (750) 750
drug therapy, combination (746) 746
tyrosine kinase (746) 746
chemistry, medicinal (737) 737
fusion proteins, bcr-abl - genetics (730) 730
pharmacokinetics (723) 723
genetic aspects (721) 721
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19377) 19377
Japanese (413) 413
German (342) 342
French (305) 305
Chinese (182) 182
Russian (158) 158
Spanish (131) 131
Italian (114) 114
Polish (36) 36
Hungarian (33) 33
Czech (29) 29
Portuguese (22) 22
Dutch (20) 20
Danish (17) 17
Turkish (14) 14
Swedish (13) 13
Norwegian (10) 10
Croatian (8) 8
Ukrainian (8) 8
Hebrew (7) 7
Romanian (6) 6
Finnish (5) 5
Bulgarian (4) 4
Korean (3) 3
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Head & Neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No effective systemic treatment... 
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | SURGERY | HISTONE DEACETYLASE INHIBITOR | SUBEROYLANILIDE HYDROXAMIC ACID | ABL TYROSINE KINASE | PROTEASOME INHIBITION | CELL-CYCLE ARREST | VALPROIC ACID | DEPSIPEPTIDE FR901228 | PHASE-II TRIAL | OTORHINOLARYNGOLOGY | IMATINIB MESYLATE | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 50, pp. 109 - 117
... are approved for first-line or later-line use in the treatment of patients with mRCC [1–3] . Among these agents, 1 is a monoclonal antibody targeting vascular endothelial... 
Hematology, Oncology and Palliative Medicine | Prognostic markers | Predictive markers | Sequential therapy | Overall survival | Targeted therapy | mRCC | PROGRESSION-FREE SURVIVAL | 1ST-LINE SUNITINIB | BLIND PHASE-III | OPEN-LABEL | INTERFERON-ALPHA | ONCOLOGY | 2ND-LINE TREATMENT | EXPRESSION LEVELS | CANCER-SPECIFIC SURVIVAL | CLINICAL-PRACTICE | DOSE TITRATION | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Vascular Endothelial Growth Factor A - genetics | Sunitinib | Tumor Suppressor Proteins - genetics | Biomarkers, Tumor - metabolism | Axitinib | Everolimus - therapeutic use | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Pyrroles - therapeutic use | Molecular Targeted Therapy - methods | Pyridines - therapeutic use | Histone-Lysine N-Methyltransferase - genetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Receptors, CCR4 - genetics | Interferon-alpha - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Transcription Factors - genetics | Ubiquitin Thiolesterase - genetics | Carcinoma, Renal Cell - metabolism | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Nivolumab | Sorafenib | Indoles - therapeutic use | Kidney Neoplasms - pathology | MicroRNAs - genetics | Quinolines - therapeutic use | Mutation | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Precision Medicine - methods | Immunologic Factors - therapeutic use | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Patient outcomes | Cancer
Journal Article
Arthritis Care and Research, ISSN 2151-464X, 01/2019, Volume 71, Issue 1, pp. 2 - 29
Objective To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between... 
RHEUMATOID-ARTHRITIS | MODIFYING ANTIRHEUMATIC DRUGS | CHRONIC PLAQUE PSORIASIS | PHASE-III | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY | NECROSIS-FACTOR INHIBITORS | QUALITY-OF-LIFE | RHEUMATOLOGY | PATIENT-REPORTED OUTCOMES | Occupational Therapy | Arthritis, Psoriatic - epidemiology | Glucocorticoids - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Infliximab - therapeutic use | Inflammatory Bowel Diseases - epidemiology | Exercise | Societies, Medical | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Physical Therapy Modalities | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Enthesopathy - therapy | Comorbidity | Rheumatology | Spondylitis - therapy | Evidence-Based Medicine | Ustekinumab - therapeutic use | Adalimumab - therapeutic use | Interleukin-17 - antagonists & inhibitors | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Weight Loss | Abatacept - therapeutic use | Diabetes Mellitus - epidemiology | Diabetes Mellitus - therapy | Inflammatory Bowel Diseases - therapy | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Arthritis, Psoriatic - therapy | Etanercept - therapeutic use | Smoking Cessation
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 17, pp. 1486 - 1494
Background Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF). Methods and... 
Heart failure | Stroke | Sinus rhythm | Atrial fibrillation | Risk factors | Ventricular ejection fraction | heart failure | risk factors | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR SYSTOLIC FUNCTION | RANDOMIZED-TRIAL | NATRIURETIC PEPTIDE | stroke | ASPIRIN | atrial fibrillation | CONVERTING-ENZYME INHIBITORS | THERAPY | WARFARIN | EJECTION FRACTION | ventricular ejection fraction | sinus rhythm | PERIPHERAL VASCULAR DISEASE | CANDESARTAN | THROMBOEMBOLISM | Follow-Up Studies | Humans | Middle Aged | Male | Diabetes Mellitus, Type 1 - complications | Peptide Fragments - blood | Aged, 80 and over | Adult | Female | Stroke - epidemiology | Natriuretic Peptide, Brain - blood | Benzimidazoles - therapeutic use | Heart Failure - complications | Stroke - prevention & control | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Rosuvastatin Calcium | Biomarkers - blood | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Stroke Volume | Cardiovascular Agents - therapeutic use | Stroke - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Fatty Acids, Omega-3 - therapeutic use | Tetrazoles - therapeutic use | Aged | Fluorobenzenes - therapeutic use | Fatty Acids | Peptide Fragments/ blood | Omega-3/ therapeutic use | Tetrazoles/therapeutic use | Sulfonamides/ therapeutic use | Kardiologi | 80 and over | Biological Markers/blood | Natriuretic Peptide | Pyrimidines/ therapeutic use | Cardiovascular Agents/therapeutic use | Stroke/epidemiology/ etiology/prevention & control | Benzimidazoles/therapeutic use | Diabetes Mellitus | Type 1/complications | Brain/ blood | Cardiac and Cardiovascular Systems | Atrial Fibrillation/etiology | Fluorobenzenes/ therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic use | Heart Failure/complications/ drug therapy
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, p. CD012657
Journal Article
European Urology, ISSN 0302-2838, 2011, Volume 61, Issue 5, pp. 950 - 960
...) progression has led to the recognition of multiple molecular targets and advances in the therapeutic landscape... 
Urology | Molecular targets | Chemotherapy | Immunotherapy | Androgen pathway inhibitors | Biologic agents | Androgen receptor | Prostate cancer | Skeletal-related events | ADVANCED SOLID TUMORS | DOCETAXEL | PATHWAY ACTIVATION | MITOXANTRONE PLUS PREDNISONE | INHIBITION | RANDOMIZED PHASE-II | CLINICAL-TRIALS | UROLOGY & NEPHROLOGY | END-POINTS | HIGH-DOSE CALCITRIOL | Receptors, Vascular Endothelial Growth Factor | Anilides - therapeutic use | Phenylthiohydantoin - therapeutic use | Humans | Ipilimumab | Recombinant Fusion Proteins - therapeutic use | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Abiraterone Acetate | Quinolones | Antibodies, Monoclonal, Humanized | Taxoids - therapeutic use | Cancer Vaccines - therapeutic use | Clinical Trials, Phase III as Topic | Bone Neoplasms - drug therapy | Clusterin - therapeutic use | Prostatic Neoplasms - drug therapy | Carcinoma - secondary | Pyridines - therapeutic use | Carcinoma - drug therapy | Dasatinib | Prostatic Neoplasms - pathology | Prostatic Neoplasms - surgery | Carcinoma - surgery | Treatment Outcome | Vaccines, Synthetic - therapeutic use | Tissue Extracts - therapeutic use | Denosumab | Radium - therapeutic use | Phenylthiohydantoin - analogs & derivatives | Orchiectomy | Pyrimidines - therapeutic use | Androstadienes - therapeutic use | Quinolines - therapeutic use | Medical colleges | Hospitals | Development and progression | Metastasis | Tubulins | Cancer | Landscape | Conferences | Immunoregulation | Clinical trials | Data processing | Oncology | Src protein | Clusterin | Metastases | Angiogenesis | Signal transduction | Androgens | Antagonism | Databases | Reviews | Tubulin | Acetic acid
Journal Article
Chest, ISSN 0012-3692, 03/2016, Volume 149, Issue 3, pp. 756 - 766
Journal Article
Journal Article